Type 1 Diabetes Gene-Edited Cell Models for Drug Discovery

Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by the destruction of pancreatic beta cells, leading to insulin deficiency. According to the World Health Organization (WHO), approximately 8.4 million people worldwide were living with T1D in 2021, with an estimated 1.5 million new cases diagnosed annually. The incidence is increasing by 2-3% per year globally, particularly in children under 15. The disease imposes a significant burden: patients require lifelong insulin therapy, and complications include cardiovascular disease, nephropathy, retinopathy, and neuropathy. The 5-year survival rate for T1D patients with good glycemic control is >95%, but life expectancy is reduced by 11-13 years compared to the general population (NCI SEER data). Key risk factors include genetic predisposition (HLA-DQ2/DQ8 alleles), environmental triggers (viral infections, diet), and a dysregulated immune response.

T1D is an ideal model for studying autoimmune mechanisms, beta cell biology, and immune tolerance. The disease has well-defined subtypes based on age of onset, autoantibody profiles (GAD65, IA-2, ZnT8), and HLA haplotypes. Public datasets such as the T1D Exchange, TEDDY study, and the Diabetes Research Institute provide rich clinical and genomic data. Open questions include the precise triggers of beta cell destruction, the role of regulatory T cells (Tregs), and strategies for beta cell regeneration. Gene-edited cell models enable researchers to dissect the molecular pathways underlying beta cell dysfunction and immune attack.

The pathogenesis of T1D involves a complex interplay between genetic susceptibility and environmental triggers. The major pathways include:

1. Antigen presentation and T cell activation:

• • HLA class II molecules (DQ2, DQ8) present beta cell antigens (e.g., insulin, GAD65) to CD4+ T cells.
• • Autoreactive T cells escape central tolerance and infiltrate pancreatic islets (insulitis).

2. Beta cell destruction:

• • CD8+ cytotoxic T cells directly kill beta cells via perforin/granzyme and Fas/FasL pathways.
• • Inflammatory cytokines (IFN-gamma, TNF-alpha, IL-1beta) induce beta cell apoptosis and oxidative stress.

3. Loss of immune regulation:

• • Defective regulatory T cell (Treg) function fails to suppress autoreactive effector T cells.
• • B cells produce autoantibodies that contribute to immune complex formation and opsonization.

Data from TCGA (pancreatic cancer), ClinVar, and genome-wide association studies (GWAS) on T1D (NCBI Gene).

Key signaling networks involved in T1D pathogenesis:

• • NF-kB pathway: Activated by inflammatory cytokines (IL-1beta, TNF-alpha) in beta cells, leading to pro-inflammatory gene expression and apoptosis.
• • JAK/STAT pathway: IFN-gamma signaling via JAK1/2 and STAT1 induces MHC class I upregulation and chemokine production.
• • PI3K/AKT/mTOR pathway: Impaired insulin signaling in beta cells reduces survival and proliferation.
• • MAPK pathway (ERK, JNK, p38): Stress-activated kinases mediate beta cell apoptosis in response to oxidative and ER stress.
• • Fas/FasL pathway: Upregulation of Fas on beta cells and FasL on T cells triggers caspase-dependent apoptosis.

Organoid models: 3D pancreatic islet organoids derived from iPSCs or adult stem cells recapitulate beta cell architecture and allow co-culture with immune cells. They provide a more physiologically relevant system for studying T1D mechanisms and drug responses.

Animal models for T1D research:

• • Non-obese diabetic (NOD) mouse: Spontaneously develops autoimmune diabetes, closely mimics human T1D. Used for immune intervention studies.
• • NOD-scid/IL2rg-/- (NSG) mouse: Immunodeficient, allows human immune system engraftment (humanized mice).
• • Streptozotocin (STZ)-induced mouse: Chemical ablation of beta cells, used for beta cell regeneration and transplantation studies.
• • RIP-LCMV mouse: Transgenic model expressing LCMV glycoprotein under the rat insulin promoter, allows virus-induced diabetes.
• • BB rat: Spontaneously develops diabetes with lymphopenia, useful for studying T cell defects.

CRISPR/Cas9 gene editing enables the creation of isogenic cell lines with precise genetic modifications relevant to T1D. Examples include:

• • INS knockout in EndoC-betaH1 cells: Models insulin deficiency and allows study of beta cell stress responses.
• • HLA-DQ2/DQ8 knock-in in human iPSC-derived beta cells: Recapitulates high-risk haplotypes for antigen presentation studies.
• • PTPN22 R620W knock-in in Jurkat T cells: Models altered T cell receptor signaling.
• • CTLA4 knockout in Tregs: Investigates immune checkpoint failure.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing reproducible, isogenic backgrounds for functional studies, drug screening, and target validation. These models eliminate the need for laborious cloning and validation, allowing researchers to focus on disease mechanisms.

CRISPR knockout and knock-in lines are used to validate the role of candidate genes in T1D. For example:

• • INS knockout in beta cell lines confirms the requirement of insulin for glucose homeostasis and reveals compensatory mechanisms.
• • PTPN22 knockout in T cells demonstrates its role in T cell activation thresholds.
• • IL2RA knockout in Tregs shows impaired suppressive function, confirming its importance in immune regulation.

These models allow researchers to dissect gene function in a controlled genetic background.

Isogenic cell pairs (e.g., wild-type vs. INS knockout) are used for high-throughput drug screening to identify compounds that protect beta cells from immune-mediated destruction. For example:

• • Screening for small molecules that reduce cytokine-induced apoptosis in INS knockout cells.
• • Testing immune-modulatory drugs (e.g., anti-CD3, abatacept) on HLA-DQ2/DQ8 knock-in T cells.
• • Modeling resistance to autoimmune attack by overexpressing anti-apoptotic genes (BCL2, XIAP) in beta cells.

CRISPR-based synthetic lethality screens identify genes that are essential for beta cell survival under autoimmune stress. For example:

• • Genome-wide CRISPR screens in beta cell lines treated with inflammatory cytokines (IFN-gamma + IL-1beta) reveal genes whose loss sensitizes or protects cells.
• • Identification of novel autoantigens by knocking out candidate genes and measuring T cell responses.
• • Discovery of biomarkers for beta cell destruction (e.g., demethylated INS DNA) using isogenic models.